NGM Biopharmaceuticals, Inc. (NGM): Price and Financial Metrics
GET POWR RATINGS... FREE!
NGM Stock Price Chart Interactive Chart >
NGM Price/Volume Stats
|Current price||$13.78||52-week high||$27.25|
|Prev. close||$13.39||52-week low||$10.49|
|Day high||$13.85||Avg. volume||294,019|
|50-day MA||$14.41||Dividend yield||N/A|
|200-day MA||$17.57||Market Cap||1.09B|
NGM Biopharmaceuticals, Inc. (NGM) Company Bio
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
Most Popular Stories View All
NGM Latest News Stream
|Loading, please wait...|
NGM Latest Social Stream
View Full NGM Social Stream
Latest NGM News From Around the Web
Below are the latest news stories about Ngm Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NGM as an investment opportunity.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.
The FDA has granted Fast Track designation to NGM Biopharmaceuticals Inc's (NASDAQ: NGM) NGM621, a monoclonal antibody to inhibit complement C3, for geographic atrophy (GA) secondary to age-related macular degeneration. NGM Bio is currently evaluating NGM621 in its ongoing Phase 2 CATALINA study, and a topline data readout is expected in Q4 of 2022. GA is an advanced form of age-related macular degeneration characterized by progressive retinal cell loss resulting in irreversible vision loss. NGM
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy (GA) secondary to age-relate
Euclidean Capital is the family office of billionaire hedge fund manager James “Jim” Simons. The hedge fund manages the private fortunes of Jim Simons, the 28th richest person in the world with a personal net worth of $24.4 billion as of January 28. Jim Simons is said to have revolutionized investing when he left academics […]
NGM Price Returns